RZLT (Rezolute, Inc. Common Stock (NV))
Insider Trading Activity
Every open-market purchase and sale reported by RZLT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-03 | Sunil Ratilal Karnawat | Chief Commercial Officer | F | — | — |
| 2026-07-07 | BRIAN KENNETH ROBERTS | Chief Medical Officer | F | — | — |
| 2026-07-07 | Nevan C Elam | CEO | F | — | — |
| 2026-07-07 | Daron Evans | CFO | F | — | — |
| 2026-03-04 | Nevan C Elam | CEO | F | — | — |
| 2026-03-04 | BRIAN KENNETH ROBERTS | Chief Medical Officer | F | — | — |
| 2026-03-04 | Daron Evans | CFO | F | — | — |
| 2025-12-17 | BRIAN KENNETH ROBERTS | Chief Medical Officer | Buy | — | — |
| 2025-12-17 | Wladimir Hogenhuis | Director | Buy | — | — |
| 2025-12-15 | Sunil Ratilal Karnawat | Chief Commercial Officer | Buy | — | — |
| 2025-12-15 | Nevan C Elam | CEO | Buy | — | — |
| 2025-12-15 | Daron Evans | CFO | Buy | — | — |
| 2025-11-21 | Erik Harris | Director | A | — | — |
| 2025-11-21 | PHILIPPE FAUCHET | Director | A | — | — |
| 2025-11-21 | Gil M Labrucherie | Director | A | — | — |
| 2025-11-21 | BRIAN KENNETH ROBERTS | Chief Medical Officer | A | — | — |
| 2025-11-21 | Daron Evans | CFO | A | — | — |
| 2025-11-21 | Nevan C Elam | CEO | A | — | — |
| 2025-11-21 | Wladimir Hogenhuis | Director | A | — | — |
| 2025-11-21 | Young-Jin Kim | Director | A | — | — |
| 2025-11-21 | NERISSA KREHER | Director | A | — | — |
| 2025-11-21 | Sunil Ratilal Karnawat | Chief Commercial Officer | A | — | — |
| 2025-08-27 | Sunil Ratilal Karnawat | Chief Commercial Officer | A | — | — |
| 2025-06-26 | BRIAN KENNETH ROBERTS | Chief Medical Officer | Buy | — | — |
| 2025-06-24 | Daron Evans | CFO | Buy | — | — |
| 2025-06-23 | Young-Jin Kim | Director | Buy | — | — |
| 2025-06-23 | NERISSA KREHER | Director | Buy | — | — |
| 2025-06-13 | Wladimir Hogenhuis | Director | A | — | — |
| 2025-06-13 | NERISSA KREHER | Director | A | — | — |
| 2025-06-13 | Gil M Labrucherie | Director | A | — | — |
| 2025-06-12 | PHILIPPE FAUCHET | Director | A | — | — |
| 2025-06-12 | Nevan C Elam | CEO | A | — | — |
| 2025-06-12 | Daron Evans | CFO | A | — | — |
| 2025-06-12 | BRIAN KENNETH ROBERTS | Chief Medical Officer | A | — | — |
| 2025-06-12 | Young-Jin Kim | Director | A | — | — |
| 2025-04-01 | Wladimir Hogenhuis | Director | Buy | — | — |
| 2025-03-31 | Nevan C Elam | CEO | Buy | — | — |
| 2025-03-28 | Daron Evans | CFO | Buy | — | — |
| 2025-03-26 | Erik Harris | Director | A | — | — |
| 2025-02-20 | Wladimir Hogenhuis | Director | MIXED | — | — |
| 2025-02-20 | Gil M Labrucherie | Director | A | — | — |
| 2025-02-19 | PHILIPPE FAUCHET | Director | A | — | — |
| 2025-02-19 | NERISSA KREHER | Director | A | — | — |
| 2025-02-19 | Young-Jin Kim | Director | MIXED | — | — |
| 2025-02-19 | BRIAN KENNETH ROBERTS | Chief Medical Officer | A | — | — |
| 2025-02-19 | Nevan C Elam | CEO | A | — | — |
| 2025-02-19 | Daron Evans | CFO | A | — | — |
| 2024-12-18 | Daron Evans | CFO | Buy | — | — |
| 2024-12-12 | Daron Evans | CFO | Buy | — | — |
| 2024-12-10 | Daron Evans | CFO | Buy | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | Director | 8,594,336 | — |
| — | Director | 2,784,722 | — |
| — | CEO | 605,497 | — |
| — | CFO | 418,400 | — |
| — | Chief Medical Officer | 309,351 | — |
| — | Director | 119,675 | — |
| — | Director | 109,072 | — |
| — | Chief Commercial Officer | 71,173 | — |
| — | Director | 58,576 | — |
| — | Director | 55,500 | — |
| — | Director | 21,000 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the RZLT quote page; the site-wide leaderboard is on the insider transactions hub.